Derm Cases · Dermatology / Adolescent Medicine
OSCE — assessment of moderate-to-severe acne vulgaris and isotretinoin counselling
An 8-minute OSCE station on acne classification, severity grading, antibiotic stewardship, hormonal options, and safe isotretinoin initiation including pregnancy prevention and laboratory monitoring.
On this page
Study tools
Target exams
NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on acne classification, severity grading, antibiotic stewardship, hormonal options, and safe isotretinoin initiation including pregnancy prevention and laboratory monitoring.
Brief (to candidate)
A 17-year-old woman has facial and truncal inflammatory papules, pustules and several tender nodules for 2 years, with early ice-pick scars and marked distress before exams. Topical benzoyl peroxide alone failed. You have 8 minutes to grade severity, plan therapy, and counsel on isotretinoin if indicated.
[5]Candidate instructions
- Classify lesion types (comedonal vs inflammatory vs nodular) and estimate severity / scarring risk.
- Differentiate from rosacea, periorificial dermatitis, folliculitis.
- Outline stepwise treatment with antibiotic stewardship.
- Counsel on isotretinoin: indication, dose concept, duration, pregnancy prevention, labs, mood/skin side-effects.
- Address psychosocial impact and safety-net (acne fulminans, pregnancy).
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Recognition | Pilosebaceous disease: comedones + papules/pustules/nodules on face/trunk; not pure rosacea (no comedones in rosacea)[3] |
| Severity & scarring | Mild / moderate / severe (nodular); notes post-inflammatory pigmentation and scarring as treatment drivers |
| Pathophysiology brief | Follicular hyperkeratinisation, sebum, C. acnes, inflammation — links to multi-target therapy |
| Topical / systemic ladder | Topical retinoid + benzoyl peroxide ± topical antibiotic (never antibiotic monotherapy); oral antibiotics time-limited + BPO; combined oral contraceptive/spironolactone options in selected women; isotretinoin for severe/scarring/psychosocial disease[1][2] |
| Antibiotic stewardship | No long-term oral antibiotic alone; always combine with BPO; limit duration; avoid concurrent topical+oral same-class antibiotic without plan to stop[4] |
| Isotretinoin safety | Pregnancy prevention (teratogenicity); baseline/monitor LFTs and lipids; counsel dryness, photosensitivity, rare mood issues; avoid concurrent tetracyclines (pseudotumour cerebri risk) |
| Red flags / communication | Acne fulminans; suicidal ideation screen; shared decision-making; realistic timeline (weeks to improve) |
Model key actions
- Grade as moderate–severe inflammatory acne with scarring risk → escalate beyond failed BPO alone.[1]
- Prefer retinoid + BPO backbone; short oral antibiotic course only with BPO; consider isotretinoin for scarring/severe disease.[2][4]
- Full pregnancy-prevention and lab counselling before isotretinoin; document psychosocial distress and follow-up.
Common errors
- Oral antibiotic monotherapy for months without BPO/retinoid.
- Starting isotretinoin without pregnancy prevention counselling.
- Missing scarring / mental health as indications to escalate.
- Confusing with rosacea and omitting comedonal assessment.
- Combining isotretinoin + tetracycline.
References5ShowHide
- [1]Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 2024.PMID 38300170
- [2]Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 2016.PMID 26897386
- [3]Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet, 2012.PMID 21880356
- [4]Dessinioti C, Katsambas A. Antibiotics and Antimicrobial Resistance in Acne: Epidemiological Trends, New Methodologies and Impact of Clinical Guidelines. The Yale Journal of Biology and Medicine, 2022.PMID 36568833
- [5]Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials JAMA Dermatol, 2020.PMID 32320027